Frontiers in Oncology (Oct 2022)
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
- Alessio Stefani,
- Alessio Stefani,
- Geny Piro,
- Geny Piro,
- Francesco Schietroma,
- Francesco Schietroma,
- Alessandro Strusi,
- Alessandro Strusi,
- Emanuele Vita,
- Emanuele Vita,
- Simone Fiorani,
- Simone Fiorani,
- Diletta Barone,
- Diletta Barone,
- Federico Monaca,
- Federico Monaca,
- Ileana Sparagna,
- Ileana Sparagna,
- Giustina Valente,
- Giustina Valente,
- Miriam Grazia Ferrara,
- Miriam Grazia Ferrara,
- Ettore D’Argento,
- Ettore D’Argento,
- Mariantonietta Di Salvatore,
- Mariantonietta Di Salvatore,
- Carmine Carbone,
- Carmine Carbone,
- Giampaolo Tortora,
- Giampaolo Tortora,
- Emilio Bria,
- Emilio Bria
Affiliations
- Alessio Stefani
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Alessio Stefani
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Geny Piro
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Geny Piro
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Francesco Schietroma
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Francesco Schietroma
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Alessandro Strusi
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Alessandro Strusi
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Emanuele Vita
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Emanuele Vita
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Simone Fiorani
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Simone Fiorani
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Diletta Barone
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Diletta Barone
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Federico Monaca
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Federico Monaca
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Ileana Sparagna
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Ileana Sparagna
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Giustina Valente
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Giustina Valente
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Miriam Grazia Ferrara
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Miriam Grazia Ferrara
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Ettore D’Argento
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Ettore D’Argento
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Mariantonietta Di Salvatore
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Mariantonietta Di Salvatore
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Carmine Carbone
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Carmine Carbone
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Giampaolo Tortora
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Giampaolo Tortora
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- Emilio Bria
- Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy
- Emilio Bria
- Section of Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
- DOI
- https://doi.org/10.3389/fonc.2022.1026020
- Journal volume & issue
-
Vol. 12
Abstract
Lung cancer is one of the most aggressive malignancies, classified into two major histological subtypes: non-small cell lung cancer (NSCLC), that accounts for about 85% of new diagnosis, and small cell lung cancer (SCLC), the other 15%. In the case of NSCLC, comprehensive genome sequencing has allowed the identification of an increasing number of actionable targets, which have become the cornerstone of treatment in the advanced setting. On the other hand, the concept of oncogene-addiction is lacking in SCLC, and the only innovation of the last 30 years has been the introduction of immune checkpoint inhibitors in extensive stage disease. Dysregulation of cell cycle is a fundamental step in carcinogenesis, and Aurora kinases (AURKs) are a family of serine/threonine kinases that play a crucial role in the correct advance through the steps of the cycle. Hyperexpression of Aurora kinases is a common protumorigenic pathway in many cancer types, including NSCLC and SCLC; in addition, different mechanisms of resistance to anticancer drugs rely on AURK expression. Hence, small molecule inhibitors of AURKs have been developed in recent years and tested in several malignancies, with different results. The aim of this review is to analyze the current evidences of AURK inhibition in lung cancer, starting from preclinical rationale to finish with clinical trials available up to now.
Keywords
